Contact Us
Drug Search Results
More Filters [+]

Atenolol

Alternative Names: atenolol, tenormin, tenoretic 50, tenoretic 100, tenoretic
Latest Update: 2024-11-01
Latest Update Note: Clinical Trial Update

Product Description

Atenolol is a second-generation beta-1-selective adrenergic antagonist indicated in treating hypertension, angina pectoris, and acute myocardial infarction. Non-FDA-approved indications include treatment of arrhythmias, migraine prophylaxis, paroxysmal supraventricular tachycardia, alcohol withdrawal, thyrotoxicosis, and prophylaxis against secondary myocardial infarction. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK539844/)

Mechanisms of Action: ADRB1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atenolol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/07/2023

News Article

 Anxiety and Depression Treatment Market 2023 Global Demand and Emerging Trends by 2031- Actiza Pharmaceutical Private Limited, Amwell, ANI Pharmaceuticals, Inc., BetterHelp, eTherapyPro.com

09/02/2023

News Article

 Based on the latest market analysis study, the Anastrozole Tablets market can expect trustworthy insights into market size, share, volume, and likely growth paths, with a CAGR value of 9.9% over the forecast period.

09/02/2023

News Article

 Our Report on Amantadine HCl Oral market provides an in-depth analysis from 2023 to 2030, as well as its market size with projected CAGR Value of 8.7%.

09/02/2023

News Article

 Amitriptyline HCl Tablets Market Report on Market Share, Development, Production Cost, Top Key Players, Segment, Growth Factor, Organization Size, Market Share Player at a Forecasted 9.3% CAGR Forecasted from 2023 to 2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions